Computer Modeling Explains Why the Lupus Drug Voclosporin Works Better on an Empty Stomach

PBPK modeling revealed that voclosporin's reduced absorption when taken with food is likely caused by the drug sticking to food particles in the gut, confirming it should be taken on an empty stomach.

Watanabe, Ayahisa et al.·Drug metabolism and pharmacokinetics·2024·Moderate EvidenceReview
RPEP-09509ReviewModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
N=N/A (computational)
Participants
PBPK model based on clinical trial data

What This Study Found

PBPK modeling identified food adsorption in the GI tract as the primary mechanism behind voclosporin's negative food effect, successfully reproducing clinical pharmacokinetic profiles in both fasted and fed states.

Key Numbers

The PBPK model successfully reproduced clinical trial observations of reduced bioavailability in the fed state.

How They Did This

Physiologically based pharmacokinetic modeling incorporating P-glycoprotein transport, CYP3A4 metabolism, and membrane permeability data from human iPSC-derived intestinal epithelial cells. Simulations were validated against clinical trial data in fasted and fed conditions and replicated in a rat model.

Why This Research Matters

For lupus nephritis patients taking voclosporin, understanding why food reduces absorption ensures proper dosing instructions. This modeling approach could also help predict food effects for other cyclic peptide drugs in development.

The Bigger Picture

Cyclic peptides are an increasingly important drug class, but their oral absorption is notoriously unpredictable. This study demonstrates that PBPK modeling can identify specific mechanisms behind food effects for this challenging drug class, potentially guiding formulation strategies to improve oral bioavailability of future cyclic peptide drugs.

What This Study Doesn't Tell Us

Computational modeling study — conclusions depend on the accuracy of input parameters and model assumptions. Doesn't account for all sources of patient-to-patient variability. The food adsorption mechanism is proposed based on modeling fit, not directly measured.

Questions This Raises

  • ?Could formulation changes (like different excipients) overcome voclosporin's food adsorption problem?
  • ?Does this PBPK approach reliably predict food effects for other cyclic peptide drugs?
  • ?How much does the food effect vary with different types of meals (high-fat vs. low-fat)?

Trust & Context

Key Stat:
Negative food effect confirmed PBPK modeling successfully reproduced voclosporin's reduced bioavailability in fed vs. fasted states, identifying food adsorption as the cause
Evidence Grade:
Moderate evidence from computational modeling validated against clinical trial data. The model's predictions matched real-world observations, but the proposed mechanism (food adsorption) is inferred from modeling, not directly measured experimentally.
Study Age:
Published in 2024, applying current PBPK modeling techniques to a relatively new lupus nephritis drug (voclosporin was FDA-approved in 2021).
Original Title:
Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling.
Published In:
Drug metabolism and pharmacokinetics, 59, 101032 (2024)
Database ID:
RPEP-09509

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why does voclosporin work worse when taken with food?

Voclosporin is a very fat-soluble molecule. When you eat, the food in your stomach and intestines acts like a sponge that soaks up the drug before your body can absorb it. This 'food adsorption' means less drug reaches your bloodstream, so it's less effective. That's why the prescribing instructions say to take it on an empty stomach.

What is voclosporin used for?

Voclosporin (brand name Lupkynis) is a cyclic peptide immunosuppressant approved in 2021 for treating active lupus nephritis — a serious kidney inflammation caused by lupus. It's a modified version of cyclosporine with improved metabolic properties, and it's one of the first oral drugs specifically approved for lupus kidney disease.

Read More on RethinkPeptides

Cite This Study

RPEP-09509·https://rethinkpeptides.com/research/RPEP-09509

APA

Watanabe, Ayahisa; Akazawa, Takanori; Fujiu, Motohiro. (2024). Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling.. Drug metabolism and pharmacokinetics, 59, 101032. https://doi.org/10.1016/j.dmpk.2024.101032

MLA

Watanabe, Ayahisa, et al. "Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling.." Drug metabolism and pharmacokinetics, 2024. https://doi.org/10.1016/j.dmpk.2024.101032

RethinkPeptides

RethinkPeptides Research Database. "Understanding mechanisms of negative food effect for voclosp..." RPEP-09509. Retrieved from https://rethinkpeptides.com/research/watanabe-2024-understanding-mechanisms-of-negative

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.